X. Wang

发表

Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): A phase II study by the Cancer and Leukemia Group B (CALGB 30107).

A. Dudek, E. Vokes, R. Kratzke, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of capecitabine as maintenance therapy after capecitabine-based combination chemotherapy for patients with advanced esophagogastric junction adenocarcinoma.

Z. Hua, Z. Sun, B. Lu, 2015, European review for medical and pharmacological sciences.

Adjuvant chemotherapy (AC) in stage IB non-small cell lung cancer (NSCLC): Long-term follow-up of Cancer and Leukemia Group B (CALGB) 9633.

R. Schilsky, D. Sugarbaker, D. Harpole, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A pooled analysis of individual patient data (IPD) of concurrent chemoradiotherapy for limited-stage small cell lung cancer (LS-SCLC) in elderly compared to younger patients (pts) who participated in US National Cancer Institute cooperative group studies.

R. Komaki, M. Edelman, E. Vokes, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy of intra-arterial neoadjuvant chemotherapy through the superior epigastric artery in the treatment of locally advanced triple negative breast cancer.

Y. Liu, W. He, X. Wang, 2016, Neoplasma.

Experience of Definitive Chemoradiation for Oesophageal Cancer Within a Large Regional Cancer Treatment Centre: Improving Outcomes and Tolerability.

A. S. Jackson, S. Mehta, H. Sheikh, 2018, Clinical oncology (Royal College of Radiologists (Great Britain)).

Quality of life (QOL) companion to CALGB 9840: A phase III study of paclitaxel (P) via weekly 1 hour (hr) versus standard 3 hour infusion every 3 weeks with trastuzumab in the treatment of patients with/without HER-2/neu-overexpressing metastatic breast cancer.

E. Winer, A. Seidman, M. Naughton, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407.

R. Govindan, E. Vokes, R. Kratzke, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.

M. Ratain, E. Vokes, J. Ramírez, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations

T. Burns, T. Stinchcombe, G. Otterson, 2023, ESMO open.

A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC).

C. Paweletz, P. Janne, E. Vokes, 2018, Annals of Oncology.

Chemoradiotherapy (CRT) and gefitinib (G) in stage III non-small cell lung cancer (NSCLC): A CALGB stratified phase II trial.

M. Edelman, P. Janne, J. Herndon, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Induction (Ind) plus concurrent (Con) chemotherapy with high-dose (74 Gy) 3-dimensional (3-D) thoracic radiotherapy (TRT) in stage III non-small cell lung cancer (NSCLC): Preliminary report of Cancer and Leukemia Group B (CALGB) 30105.

M. Socinski, E. Vokes, J. Bogart, 2006, Journal of Clinical Oncology.

[Clinical outcomes of different irradiation ranges in definitive intensity-modulated radiotherapy for esophageal cancer].

C. Song, W. Deng, X. Wang, 2020, Zhonghua zhong liu za zhi [Chinese journal of oncology].

Eicosanoid modulation in advanced non-small cell lung cancer (NSCLC): CALGB 30203.

M. Edelman, E. Vokes, R. Kratzke, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.